GSK cancer, HIV drug sales lift 2025 outlook in boost to stock
News Source : Yahoo Entertainment
News Summary
- GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer medicines posted double digit growth.
- U.S. sales of its shingles vaccine Shingrix fell sharply, but its shares gained as much as 4.3% to their highest level since May 2024.
- The stock, which has risen 25% so far in 2025, was up 2.16% at 1040 GMT.
- GSK's improved outlook comes as CEO Emma Walmsley prepares to hand over to Luke Miels early next year.
By Bhanvi Satija and Yadarisa ShabongLONDON (Reuters) GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer medicines posted double digit growth, lifting t [+2406 chars]
Never miss a story from us, subscribe to our newsletter